Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MonumenTAL-6: talquetamab combinations versus investigator's choice in relapsed or refractory multiple myeloma
jRCT2031240026Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of talquetamab, teclistamab, pomalidomide, elotuzumab, bortezomib and 1 more in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started May 2024; status: active, not recruiting.
02
Drugs
talquetamabteclistamabpomalidomideelotuzumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031240026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240026.